Evidence map›Paper›PMID 42058075›Full record

ArticleFrontiers in public health2026

COVID-19 primary infection, reinfection, and its associated clinical presentations.

Varuni Makam, Vidyavathi B Chitharagi, Tejashree A, Morubagal Raghavendra Rao, Smitha Chandrashekarappa, Yogeesh D Maheshwarappa

Abstract read
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Varuni MakamDepartment of Microbiology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, India.
Vidyavathi B ChitharagiDepartment of Microbiology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, India.
Tejashree ADepartment of Microbiology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, India.
Morubagal Raghavendra RaoDepartment of Microbiology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, India.
Smitha ChandrashekarappaDepartment of Community Medicine, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, India.
Yogeesh D MaheshwarappaDepartment of Microbiology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2), which caused primary COVID-19 infection in millions worldwide, raised significant concerns as viral mutations emerged, leading to reinfections among previously infected and vaccinated individuals. This phenomenon became particularly evident during the second and third waves of the COVID-19 pandemic in India. Methods: The current study observed the rates of reinfections due to SARS-CoV-2 and their relation to vaccination details by retrospectively analyzing the data of patients who had reinfections during the second and third waves of COVID-19. Results: Among the 458 study participants, 62/458 (13.54%) with primary infection had confirmed re-infection. Of the 458 people infected with COVID-19 for the first time, 60 (13%) were asymptomatic and 398 (87%) were symptomatic. The most frequently observed symptoms were fever during primary (70.3%) and re-infection (72.58%). A statistically significant association was observed between vomiting symptoms and infection status ( Conclusions: SARS-CoV-2 is re-emerging with new variants and varied presentations, posing a challenge to clinicians regarding specific diagnoses. The symptoms of COVID-19 during primary and re-infection did not differ greatly. Although vaccination protects individuals against reinfections, the exact duration of protection remains unknown and may necessitate booster doses at frequent intervals.

Indexed as

COVID-19ReinfectionAdolescentAdultCOVID-19 VaccinesFemaleHumansIndiaMaleMiddle AgedRetrospective StudiesSARS-CoV-2VaccinationYoung AdultCOVID-19 VaccinesCOVID-19primary infectionreinfectionSARS-CoV-2vaccination

Identifiers

PMID42058075
PMCPMC13121108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.